11.46

0.35% -0.04

Evolus Inc (EOLS)

Overview News Price History Option Chain Discussions Forecast

Evolus Inc stock is currently priced at $11.46, with a 24-hour trading volume of 269.68K. It has seen a -0.35% decreased in the last 24 hours and a -16.96% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $11.53 pivot point. If it approaches the $11.37 support level, significant changes may occur.

Previous Close:

$11.50

Open:

$11.35

24h Volume:

269.68K

Market Cap:

$704.76M

Revenue:

$202.09M

Net Income/Loss:

$-61.69M

P/E Ratio:

-9.7949

EPS:

-1.17

Net Cash Flow:

$-35.64M

1W Performance:

-0.87%

1M Performance:

-16.96%

6M Performance:

+47.11%

1Y Performance:

+36.43%

1D Range:

$11.07

$11.48

52W Range:

$7.07

$15.43

Evolus Inc Stock (EOLS) Company Profile

Name

Evolus Inc

Sector

Healthcare (1197)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

949-284-4555

Address

17901 Von Karman Avenue, Suite 150, Irvine

Employee

Twitter

@evolusaesthetic

Next Earnings Date

2024-05-07

Latest SEC Filings

EOLS's Discussions on Twitter

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight
Jun-23-22	Initiated	Needham	Buy
May-12-22	Upgrade	Barclays	Underweight → Equal Weight
Jan-20-22	Upgrade	Truist	Hold → Buy
May-06-21	Upgrade	Mizuho	Neutral → Buy
Apr-08-21	Reiterated	H.C. Wainwright	Buy
Feb-24-21	Downgrade	Truist	Buy → Hold
Jul-07-20	Downgrade	Mizuho	Buy → Neutral
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform
Sep-05-19	Resumed	Mizuho	Buy
Jun-28-19	Initiated	Wells Fargo	Market Perform
Jun-11-19	Initiated	Barclays	Underweight
Mar-20-19	Initiated	SunTrust	Buy
Feb-14-19	Initiated	H.C. Wainwright	Buy
Jan-29-19	Initiated	Stifel	Buy

View All

Evolus Inc Stock (EOLS) Latest News

4 Stocks to Buy for Attractive Earnings Acceleration

Zacks Investment Research

Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?

Zacks Investment Research

TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday

Benzinga

Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker

Benzinga

Evolus Inc Stock (EOLS) Financials Data

Evolus Inc (EOLS) Revenue 2024

EOLS reported a revenue (TTM) of $202.09 million for the quarter ending December 31, 2023, a +35.98% rise year-over-year.

Evolus Inc (EOLS) Net Income 2024

EOLS net income (TTM) was -$61.69 million for the quarter ending December 31, 2023, a +17.10% increase year-over-year.

Evolus Inc (EOLS) Cash Flow 2024

EOLS recorded a free cash flow (TTM) of -$35.63 million for the quarter ending December 31, 2023, a +59.44% increase year-over-year.

Evolus Inc (EOLS) Earnings per Share 2024

EOLS earnings per share (TTM) was -$1.08 for the quarter ending December 31, 2023, a +18.18% growth year-over-year.

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.